Literature DB >> 1171

The renal elimination of procainamide.

R L Galeazzi, L B Sheiner, T Lockwood, L Z Benet.   

Abstract

The question of pH or flow dependence for the renal elimination of procainamide (PCA) was studied under 4 conditions in each of 4 subjects. Each subject received 500 mg of PCA intravenously at weekly intervals while in a state of (1) acid load (NH4Cl) and water deprivation, (2) acid load and water excess, (3) alkali load (NaHCO3) and water deprivation, and (4) alkali load and water excess. Plasma and urine were collected at frequent intervals for PCA and N-acetyl PCA (NAPA) analysis. Urine flow rates varied markedly between the water deprivation and water excess states (approximately 1.2 vs 5 ml/min, respectively), and urine pH varied markedly between the acid and alkali load states (pH = ca 5 vs 8, respectively). Despite this marked variation, there were no significant changes in PCA renal clearance or 24-hr PCA or NAPA excretion. If passive diffusion of PCA were taking place, such flow and pH changes would have caused marked changes in PCA clearance were the pH partition hypothesis true. We therefore conclude that passive diffusion is not an important mechanism in the renal elimination of PCA in man and that there must be tubular secretion. The implication for the clinical use of the drug is that dose adjustments need not be made in response to variations in urine flow and pH.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1171     DOI: 10.1002/cpt197619155

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  14 in total

1.  Drug kinetics and artificial kidneys.

Authors:  T B Gibson; H A Nelson
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

2.  Pharmacokinetics of sulphamethoxazole in man: effects of urinary pH and urine flow on metabolism and renal excretion of sulphamethoxazole and its metabolite N4-acetylsulphamethoxazole.

Authors:  T B Vree; Y A Hekster; A M Baars; J E Damsma; E van der Kleijn
Journal:  Clin Pharmacokinet       Date:  1978 Jul-Aug       Impact factor: 6.447

3.  Serum procainamide levels as therapeutic guides.

Authors:  J Koch-Weser
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

Review 4.  The pharmacological role of the kidney.

Authors:  D C Brater
Journal:  Drugs       Date:  1980-01       Impact factor: 9.546

5.  Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype.

Authors:  J J Lima; D R Conti; A L Goldfarb; W J Tilstone; L H Golden; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

Review 6.  Pharmacokinetics in patients with cardiac failure.

Authors:  N L Benowitz; W Meister
Journal:  Clin Pharmacokinet       Date:  1976 Nov-Dec       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of procainamide.

Authors:  E Karlsson
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

Review 8.  Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide.

Authors:  S Y Kim; N L Benowitz
Journal:  Drug Saf       Date:  1990 Nov-Dec       Impact factor: 5.606

9.  Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man.

Authors:  A Somogyi; F Bochner
Journal:  Br J Clin Pharmacol       Date:  1984-08       Impact factor: 4.335

10.  Population pharmacokinetics of procainamide from routine clinical data.

Authors:  T H Grasela; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.